Potential clinical relevance
The use of extracellular vesicles as liquid biopsies is emerging. We
have used label-free quantification proteomic characterisation to
establish that patients with single-episode VTE anticoagulated with
Rivaroxaban compared with warfarin demonstrate altered circulating EV
profiles with distinct proteomic signatures. The observed differences
may indicate a pharmacologic reduction in the pro-thrombotic state in
combination with more stable coagulation in Rivaroxaban-treated patients
relative to warfarin. These results may be of translational relevance
towards characterising the emerging anti-inflammatory and
cardiovascular-protective characteristics associated with Rivaroxaban
therapy relative to warfarin.